This is in line with other group's finding that CFZ sensitizes rituximab-resistant lymphoma cells to chemotherapy but upregulates Bcl-2 expression (Gu et al., 2013), which implies a complex modulation among these mitochondria-associated proteins to decide cell fate. The gene discussed is BCL2; the disease is lymphoma.